Business
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI Advanced pipeline indications with initiation of cardio-renal clinical trial Webcast today at 4:30 pm Eastern Time DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage
About this update from Seastar Medical Holding Corporation
[{"type":"image","alt":"SeaStar Medical","displaySize":"","headline":null,"caption":"SeaStar Medical","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/a2PlyGYjCebNG9cYp9_P4g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NA--/https://media.zenfs.com/en/globenewswire.com/4c7240b3e0b5bc01bb2108fbeef0b4c6","width":300,"height":110}},"lazy":false},{"type":"text","content":"Added top-rated children’s hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base","length":101,"tagName":"p"},{"type":"text","content":"Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry ","length":76,"tagName":"p"},{"type":"text","content":"Exceeded 50% enrollment milestone in pivotal trial of SCD therapy in adult patients with AKI ","length":92,"tagName":"p"},{"type":"text","content":"Advanced pipeline indications with initiation of cardio-renal clinical trial","length":76,"tagName":"p"},{"type":"text","content":"Webcast today at 4:30 pm Eastern Time","length":37,"tagName":"p"},{"type":"text","content":"DENVER, March 25, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today financial results for the three months and year ended December 31, 2025, and provided business updates on key initiatives.","length":381,"tagName":"p"},{"type":"text","content":"“In 2025, we broadened our customer base of top-ranked children’s hospitals, continued enrollment in the NEUTRALIZE-AKI pivotal clinical trial, and advanced our pipeline with the initiation of the cardio-renal clinical trial of our selective cytopheretic device (SCD) therapy,” said Eric Schlorff, CEO of SeaStar Medical. “We move into 2026 with strong momentum and key value creating milestones that will not only impact our success but also advance our mission to bring a potential life-saving therapy to patients who would otherwise have little hope of survival.”","length":566,"tagName":"p"},{"type":"text","content":"Mr. Schlorff continued, “I want to acknowledge the dedication and tenacity of our team for surpassing the 50% enrollment milestone of the...